ELAVL1 and cancer: Niclosamide can boost the death of cancer cells by T lymphocytes and improve the effectiveness of anti-PD-1 immunotherapy by preventing the movement of HuR to the cytoplasm and reducing the glycosylation of PD-L1 [67].